dismiss

Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
当前地点:
>
> This Story


注册记数器 to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Molecular Imaging Homepage

Louisiana getting $14 million Center for Molecular Imaging and Therapy Increasing research opportunities, collaboration and radiopharmaceuticals

PET uncovers abnormal tau deposits associated with CTE in live subjects May enable diagnosis of CTE in living people one day

DOE transfers land to Coquí Pharma for isotope production facility Will be used primarily to produce Mo-99

Amyloid PET scans help with Alzheimer's clinical management New insights from the 11,000 patient IDEAS study

United Imaging's total-body PET scanner shows promise in four new studies Faster scans, lower dose and 'a level of detail never seen in PET'

NorthStar buys IBA electron accelerators for Mo-99 production Will increase production capacity and efficiencies

RadioMedix and Vect-Horus to develop brain theranostic agent for brain cancer Provide diagnosis and treatment of Glioblastoma Multiforme (GBM)

NIH awards $1.8 million to Magnetic Insight for neurovascular MPI Detects magnetic nanoparticle tracers, enables deep-tissue imaging

DOE to cut Moly-99 deals with four US firms Could be as much as $15 million per company, with partners matching awarded amounts

Women's brains appear three years younger than men's at the same age: PET study A machine-learning algorithm assisted with the analysis

Denos Health Management
launches Zionexa

Following Cyclopharma sale, Denos launches radiopharmaceutical company, Zionexa

John R. Fischer , Staff Reporter
Denos Health Management, the former primary stakeholder of PET diagnostics manufacturer Cyclopharma France and U.S., is starting from scratch in the radiopharmaceutical industry following its sale of the French-based enterprise, with the launch of Zionexa.

Formerly the U.S. division of Cyclopharma, the new company will focus on clinically developing and commercializing innovative companion diagnostic and therapeutic radiopharmaceuticals to enhance patient care. Its establishment follows the recent acquisition of Cyclopharma by Curium.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



“It was the right time,” Peter Webner, Zionexa CEO and former CEO of Cyclopharma U.S., told HCB News. “They were looking to get their equity out. Curium was looking at growing its footprint and a decision was made at the board level for Cyclopharma that they wanted to focus on the new products coming down the pipe.”

Announced in April and completed in May, the deal provided Curium access to nearly 100 employees and seven PET radiopharmacies throughout France, enabling it "comprehensive coverage of all 140 PET centers across France,” as stated in its announcement of the transaction.

Existing R&D and international operations of Cyclopharama though were not included in the agreement.

In addition to acquiring Cyclopharma’s U.S. division, Denos Health Management purchased the rights to the pipeline of Cyclopharma France, including EstroTep, a PET tracer cleared for use only in France.

Denos Health Management also adds value from early pharmacodynamics studies (Phase 0), early human kinetics and dosimetry and proof of concept imaging (Phase 1), target development and process and chemistry improvement (Phase 2), pivotal clearance trials (Phase 3), commercialization and distribution, and market access strategy.

Zionexa plans to gain FDA clearance for EstroTep and is currently working on clinical trials for several other products including IMAKinib, designed to target the EGFR protein in lung cancer.

A third product is also in the works. Webner could not comment on it at this time but did say that all three are fluorine-based and would “fit naturally into the mix of commercial and academic cyclotron capabilities in the U.S.”

EstroTep is planned as the first of the three to be submitted to the FDA for market clearance.

Submissions are set to begin this summer.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

做广告
提升您的品牌知名度
拍卖+私人销售
获得最好的价格
买设备/配件
找到最低价格
每日新闻
阅读最新信息
目录
浏览所有的DOTmed用户
DOTmed上的伦理
查看我们的伦理计划
金子分开供营商节目
接收PH要求
金子服务经销商节目
接收请求
提供保健服务者
查看所有的HCP(简称医疗保健提供商)的工具
工作/训练
查找/申请工作
Parts Hunter +EasyPay
获取配件报价
最近证明
查看最近通过认证的用户
最近额定
查看最近通过认证的用户
出租中央
租用设备优惠
卖设备/配件
得到最划算
服务技术员论坛
查找帮助和建议
简单的征求建议书
获取设备报价
真正商业展览
查找对设备的服务
对这个站点的通入和用途是受期限和条件我们支配 法律公告 & 保密性通知
物产和业主对 DOTmed.com,公司 Copyright ©2001-2019 DOTmed.com, Inc.
版权所有